Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilysys Inc (AGYS) vs Danaher Corporation (DHR) Price & Performance

Agilysys IncTrade
Danaher CorporationTrade

Price performance (Past 24H)

Key statistics

Agilysys Inc vs Danaher Corporation — how do they compare? Agilysys Inc trades at $107.52 (market cap $3.00B), while Danaher Corporation trades at $207.45 (market cap $145.83B). The key difference: Danaher Corporation is far larger — about 48.6× Agilysys Inc's market cap, and Danaher Corporation pays a 0.77% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.

AGYSDHR
Market Cap
$3.00B$145.83B
Sector
TechnologyHealth
52-Week High
$141.12$242.05
52-Week Low
$62.19$161.91
Enterprise Value
$2.90B$168.04B
Dividend Yield
0.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agilysys Inc

Agilysys (AGYS) trades at $107.35, up 0.35% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q1 and Q2 2026 earnings beats, record subscription revenue growth, and improved FY27 guidance. Technical indicators suggest bullish momentum with support at $106 and resistance at $108. The company's hospitality software solutions are gaining traction through partnerships and AI-driven innovation.

Outlook remains positive with 100% analyst buy ratings and $118.33 consensus price target representing 10.2% upside. Key opportunities include subscription revenue growth and Marriott deployment progress, while risks include execution challenges and competitive pressures in the hospitality technology sector.

Danaher Corporation

Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.

The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.

Returns comparison

Trailing returns across standard periods

About Agilysys Inc

Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.

Read more on AGYS

About Danaher Corporation

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.

Read more on DHR